2001
Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy?
Zheng F, Cai W, Mitsuhashi T, Vlassara H, Bucala R. Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy? Molecular Medicine 2001, 7: 737-747. PMID: 11788787, PMCID: PMC1950004, DOI: 10.1007/bf03401963.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsSerum advanced glycation endproductsDb/db miceNon-obese diabeticSerum AGEsMesangial cellsDb miceAGE-BSAGlycation endproductsIGF-I productionDiabetic renal damageSprague-Dawley ratsAGE clearanceSuppress macrophagesNOD miceDiabetic nephropathyRenal damageRenal excretionNormal ratsMMP-9Type IV collagenHost defense proteinsExcretionMRNA levelsMice
1997
Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
Koschinsky T, He C, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 6474-6479. PMID: 9177242, PMCID: PMC21074, DOI: 10.1073/pnas.94.12.6474.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsDietary advanced glycation endproductsEndogenous advanced glycation endproductsDiabetes mellitusKidney diseaseRenal excretionRenal vascular injuryDiabetic nephropathy patientsSerum AGE levelsDegree of albuminuriaNondiabetic kidney diseaseEnvironmental risk factorsAGE immunoreactivityRenal complicationsCreatinine clearanceDiabetic nephropathyNephropathy patientsRenal failureDiabetic patientsRisk factorsFood intakeHealthy subjectsGlycation endproductsDietary restrictionCL diet
1995
Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes
Beisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes. Diabetes 1995, 44: 824-829. PMID: 7789650, DOI: 10.2337/diab.44.7.824.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsEnzyme-linked immunosorbent assayAlbumin excretionDuration of diabetesElevated levelsNormal renal statusTissue advanced glycosylation end productsDiabetic vascular complicationsTissue AGE levelsGlycosylation end productsEvident retinopathyMicroalbuminuric phaseOvert microangiopathySevere retinopathyVascular complicationsDiabetic nephropathyRenal statusUrinary albuminProliferative retinopathyEarly retinopathyHigher age levelsSignificant elevationRetinopathyRetinal diseasesEarly manifestation
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingBiomarkersDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycosylationGuanidinesHemoglobinsHumansMiddle AgedConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes